SAB Biotherapeutics, Inc. Common Stock
SABSSAB Biotherapeutics, Inc. (SABS) is a biotechnology company specializing in developing and manufacturing innovative antibody-based therapeutics. The company leverages its proprietary platform to produce fully-human, polyclonal antibodies derived from transchromosomic cattle, aimed at treating infectious diseases and providing immune protection. SAB Biotherapeutics focuses on rapid response to emerging health threats and enhancing immune treatments through its advanced biopharmaceutical technologies.
Company News
SAB Biotherapeutics announced the pricing of an $85 million public offering consisting of 19.3 million shares at $3.85 per share and pre-funded warrants. The company plans to use proceeds to fund development of SAB-142, its clinical-stage candidate for type 1 diabetes, through ongoing Phase 2b trials and related activities. The offering is expect...
SAB Biotherapeutics (Nasdaq: SABS) announced a public offering of 19.3 million shares at $3.85 per share and 2.75 million pre-funded warrants, expected to raise approximately $85 million in gross proceeds. The company plans to use the funds to advance development of SAB-142, its lead candidate for type 1 diabetes, through ongoing clinical trials ...
SAB Biotherapeutics announced that its management team will participate in two investor conferences in February 2026: the Guggenheim Securities Emerging Outlook: Biotech Summit on February 11 and the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25. The company is developing SAB-142, a human anti-thymocyte immunoglobulin...
SAB Biotherapeutics announced the appointment of David Zaccardelli, Pharm.D. as Board Chair and Rita Jain, M.D. as an independent director, effective immediately. Zaccardelli brings over 20 years of biopharmaceutical executive experience, including leading the successful launch of Ohtuvayre® at Verona Pharma. Jain is a rheumatologist with two de...
SAB Biotherapeutics reported positive Phase 1 trial results for SAB-142, a potential treatment for type 1 diabetes, demonstrating safety, low immunogenicity, and no serum sickness across healthy volunteers and patients.
